NeuBase Therapeutics, Inc entered into a Subscription and Investment Representation Agreement of Series A Preferred Stock, par value $0.0001 per share, for $1 per share for gross proceeds $1 on May 29, 2024. The Series A Preferred Stock is not convertible into shares of Common Stock or any other class or series of stock of the Company. The transaction includes participation from single investor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3406 EUR | -0.58% |
|
-.--% | -45.94% |
1st Jan change | Capi. | |
---|---|---|
-45.94% | 13.91L | |
+38.36% | 5.27TCr | |
+36.73% | 3.9TCr | |
-8.63% | 3.85TCr | |
+25.46% | 3.04TCr | |
-11.17% | 2.64TCr | |
+11.44% | 2.61TCr | |
+45.09% | 1.42TCr | |
+32.93% | 1.26TCr | |
-5.30% | 1.15TCr |
- Stock Market
- Equities
- O7P Stock
- News NeuBase Therapeutics, Inc.
- NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding